全球静脉支架市场 - 市场规模（按细分市场划分）、占有率、监管、报销、介入治疗及预测（至 2036 年）

本报告对全球静脉支架市场进行了考察和分析，提供了区域市场规模、关键趋势、创新产品和技术以及竞争格局等资讯。

市场模型的主要组成如下：

已上市的静脉支架及不断变化的竞争格局

• 关键产业趋势探讨
• 静脉支架市场各细分市场的年度收入和市场展望（2015-2036 年）
• 各细分市场的总手术量、单位销售、平均售价及市场价值的详细数据

全球、区域与国家层面的市场探讨

• 细分市场的定性资讯按地区和国家/地区划分的全球趋势讨论
• 静脉支架市场 SWOT 分析
• 静脉支架市场竞争动态讨论及趋势

全面的视角，包括对医疗保健系统的概述，有助于深入了解市场。此外，市场参与部分提供有关报销政策和监管环境的信息，从而可以更深入地了解市场动态。

• 各国医疗保健系统概述
• 报销政策
• 各国医疗科技监管环境

目标公司

• Boston Scientific Corp
• Becton Dickinson and Co
• CR Bard Inc
• Cook Medical Inc
• Medtronic Plc
• OptiMed Medizinische Instrumente GmbH
• Plus Medica GmbH

Venous Stents Market Size by Segments, Share, Regulatory, Reimbursement, Interventions and Forecast to 2036 is built to visualize quantitative and qualitative market trends within Cardiovascular Devices therapeutic area.

A venous stent is a self-expandable metallic stent with perforated tube which is inserted into a vein to prevent the blood flow constriction caused by obstructions and occlusions in the venous vasculature. Venous stent placement is considered in case of significant stenosis or extrinsic compression. Venous stents placed in the iliofemoral vein have been tracked in this market.

Chronic Venous Disease (CVD) or Chronic venous insufficiency (CVI) has emerged as a global burden on developing and developed countries. It refers to the condition where venous walls and/or valves in the leg are not working efficiently and becomes increasingly difficult for blood to return to the heart from the legs. Deep Vein Thrombosis (DVT) is a potential life threating condition where a blood clot is formed in the large deep veins in the body. Most of the DVT occurs proximal or distal to the iliofemoral vein as well as in the pelvic area. They also can occur in other parts of the body. Deep Vein Thrombosis (DVT) can be characterized as acute/subacute and chronic. Venous stent placement is considered in case of significant stenosis or extrinsic compression.

Each of the covered 39 country's color-coded and fully-sourced market models are equipped with epidemiology based indications with intervention volumes. The interactive excel deliverable covers installed base, new sales volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.

Key Inclusions of the market model are -

Currently marketed Venous Stents market and evolving competitive landscape -

• Insightful review of the key industry trends.
• Annualized total Venous Stents market revenue by segment and market outlooks from 2015-2036.
• Granular data on total interventions, units, average selling prices and market values by segment.

Global, Regional and Country level market specific insights -

• Qualitative market specific information is available with global trends further broken down into regional trends. In addition GlobalData analysts provide unique country specific insights on the market.
• SWOT analysis for Venous Stents market.
• Competitive dynamics insights and trends provided Venous Stents market.

Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.

• Country specific overview of the healthcare system.
• Country specific reimbursement policies.
• Country specific medtech regulatory landscape.

Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.

Companies covered: Boston Scientific Corp, Becton Dickinson and Co, CR Bard Inc, Cook Medical Inc, Medtronic Plc, OptiMed Medizinische Instrumente GmbH, Plus Medica GmbH.

Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina, and Chile.

Scope

This Market Model gives important, expert insight you won't find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for:

• CMO executives who must have deep understanding of the Venous Stents marketplace to make strategic planning and investment decisions.
• Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
• Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.

Reasons to Buy

The model will enable you to -

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products, by identifying key companies.
• Develop business strategies by understanding the trends shaping and driving Venous Stents market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Venous Stents market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the company share of market leaders.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Track device sales in the global and country-specific Venous Stents market from 2015-2036.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.